Want to join the conversation?
$ANIP announced launch of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL indicated as a treatment for various infections that are caused by susceptible strains of selected diseases. $ANIP will immediately launch the product. According to IMS Health, the current annual U.S. market for this product is about $78MM.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.